The mid-stage misfire of Alto Neuroscience’s depression candidate ALTO-100 is not just bad – and predictable given that the asset had already failed in the disease – it also calls into question the company’s whole raison d’etre.
Key Takeaways
- The Phase II trial of Alto Neuroscience’s brain-derived neurotrophic factor modulator ALTO-100 in major depression has failed, wiping 65% off the company’s value.
- The molecule had already failed in a similar trial in 2017, when it was owned by Neuralstem
Alto has been attempting to use biomarkers to tailor its treatments to individual patients as a way to mitigate the heterogeneous presentation of neuropsychiatric disorders
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?